View Older Stories View More Recent Stories
-
Roth Capital Starts Response Genetics (RGDX) at Buy
-
Roth Capital Upgrades Capstone Turbine (CPST) to Buy
-
Roth Capital Starts QuickLogic (QUIK) at Buy
-
Roth Capital Starts Redhill Biopharma (RDHL) at Buy
-
Roth Capital Starts TG Therapeutics (TGTX) at Buy
-
Roth Capital Downgrades GSI Group (GSIG) to Neutral
-
Roth Capital Starts Verastem (VSTM) at Buy
-
Roth Capital Downgrades World Wrestling Entertainment (WWE) to Neutral
-
Roth Capital Downgrades Vitacost.com (VITC) to Sell
-
Roth Capital Starts Cytori Therapeutics, Inc. (CYTX) at Buy
-
Wireless Ronin (RNIN) Sinks on $1.56M Offering
-
Roth Capital Resumes Perry Ellis (PERY) at Buy
-
Limoneira (LMNR) Underwriters Exercise Full Overallotment in Equity Offering
-
Roth Capital Upgrades CIBER (CBR) to Buy
-
Roth Capital Upgrades inContact (SAAS) to Buy
-
Roth Capital Starts Endocyte (ECYT) at Buy
-
Plug Power (PLUG) Prices 18.9M Common, Warrants Offering; Sees Gross Proceeds of $2.8M
-
eGain (EGAN) Prices 2.17M Common Offering at $6.75/Share
-
Roth Capital Downgrades Meredith Corp (MDP) to Neutral
-
Roth Capital Starts Hydrogenics (HYGS) at Buy
-
Notable Analyst Rating Changes 02/08: (ATVI) (UDR) (GES) Upgraded; (NUAN) (SKUL) (CYS) Downgraded
-
Roth Capital Downgrades Skullcandy (SKUL) to Neutral
-
Roth Capital Downgrades RTI Biologics (RTIX) to Neutral
-
Roth Capital Assumes Delta Apparel (DLA) at Buy
-
Silver Bull (SVBL) Affirms Full Allocation of 22.75M Unit Offering
-
Roth Capital Starts Comstock Mining (LODE) at Buy
-
Roth Capital Upgrades A.T. Cross Company (ATX) to Buy
-
Limoneira (LMNR) Anounces 1.8M Common Offering
-
Roth Capital Downgrades Graham Corporation (GHM) to Neutral
-
Roth Capital Downgrades Celsion Corp (CLSN) to Neutral
-
Notable Analyst Rating Changes 01/31: (FB) (VALE) (AJG) Upgraded; (RF) (PCLN) (VELT) Downgraded
-
Roth Capital Resumes Joe's Jeans Inc. (JOEZ) at Buy
-
Keryx Biopharma (KERX) Prices 8.23M Offering at $8.49/Share
-
Keryx Biopharmaceuticals (KERX) Continues Monumental Run-Up; Analysts See Another 40% Upside
-
Keryx Biopharmaceuticals (KERX) Gets Another 'Going to $15' Call
-
Streetinsider.com's Hot Lunchtime Reads 01/28: (GM) (GRPN) (LVS) (KERX) (SODA)
-
Roth Capital Doubles PT on Keryx (KERX); Sees Another 200% Upside
-
Roth Capital Downgrades Trinity Biotecjh (TRIB) to Neutral
-
Notable Analyst Rating Changes 01/16: (NFX) (PLXT) (DDR) Upgraded; (YELP) (AAPL) (IRWD) Downgraded
-
Roth Capital Upgrades PLX Technology (PLXT) to Buy
-
Roth Capital Resumes Glu Mobile (GLUU) at Buy
-
Roth Capital Downgrades ClickSoftware (CKSW) to Neutral
-
Notable Analyst Rating Changes 01/07: (AMZN) (WAG) (INTC) Upgraded; (YHOO) (LOW) (ASML) Downgraded
-
Roth Capital Upgrades Peregrine Pharmaceuticals (PPHM) to Buy
-
Roth Capital Starts SolarCity (SCTY) at Buy
-
Roth Capital Starts Navarre Corp. (NAVR) at Buy
-
Roth Capital Starts ImmunoCellular Therapeutics (IMUC) at Buy
-
Roth Capital Starts EMCORE (EMKR) at Buy
-
Roth Capital Starts ExactTarget (ET) at Buy
-
Sentiment Behind FDA Approval of Alexza's (ALXA) Adusave Improves; Shares Higher Today

